[Individualization of polychemotherapy for stage III breast cancer based on immunologic status]

|January 1, 1984

Abstract:

Immunologic response was studied in 91 cases of stage III breast cancer who received a CFMVP polychemotherapy. 23 patients were given decaris for immunostimulation. All cases showed a significant decrease in cellular immunity. CFMVP-treated patients showing a decrease of 30% and more should receive 300 mg of decaris twice a week for 3 weeks.

Related Experiment Videos

[Individualization of polychemotherapy for stage III breast cancer based on immunologic status]

Related Concept Videos

[Comparative evaluation of the lymphocyte blast-transformation reaction induced by various mitogens in the polychemotherapy of patients with breast cancer].

[Diagnostic errors in patients with giant-cell tumor, bone cyst and osteosarcoma].

[Inhibitory effect of RHAMM-target peptides on invasion of breast cancer cells].

[Influence of acetylcholine and adrenergic receptors on development and progression of non-small cell lung cancer].

[Automated contact radiation therapy - conditions for effective use in practical healthcare].

[Possibilities of local hyperthermia in treatment for edematous breast cancer patients].

[Experience of 100 transthoracic needle biopsies of the lung under CT navigation].

A Markov model cost threshold analysis of potential hepatitis B virus cure regimens.

Efficacy and safety of radiofrequency hyperthermia combined with immune checkpoint inhibitors and chemotherapy as first-line treatment for HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma: A propensity score-matched study.

Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Metastatic Well-Differentiated Neuroendocrine Tumors.

Clinical outcomes and blood-based biomarkers across two SABR-treated metastatic settings: oligoprogression under immune checkpoint inhibition and oligometastatic disease.

Is there a role for palliative care in CAR T-cell therapy?

Synergistic Antitumor Effects and Reduced Systemic Toxicity of Berberine Chloride Combined With Cisplatin in a Female BALB/c Mouse Xenograft Model.

Related Experiment Videos

[Individualization of polychemotherapy for stage III breast cancer based on immunologic status]

Abstract:

Related Concept Videos

Related Articles